Clinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipAs biologic therapies for severe asthma, monoclonal antibodies targeting key type‑2 inflammatory pathways, have transformed treatment, they remain costly and not without potential adverse effects; therefore, their optimal use requires careful patient selection based on objective criteria (e.g., adherence assessment, biomarker profile, corticosteroid responsiveness) rather than symptom reporting alone [1][2]. In clinical practice, poor adherence to inhaled corticosteroids (ICS) is well documented among patients with difficult‑to‑control asthma and contributes to persistent symptoms and exacerbations, complicating the identification of patients with true corticosteroid‑resistant disease who might benefit most from biologic therapy [3][4][5][6].
For this reason, stratified management protocols that systematically assess treatment adherence and corticosteroid responsiveness are recommended in international and national asthma guidelines before considering initiation of biologics, as they help improve targeting of advanced therapies and avoid unnecessary escalation [5][6][7][8].
One of the major goals of the UK Refractory Asthma Stratification Programme (RASP‑UK) over the past 3 years has been to develop and validate such protocols, focusing on methods that distinguish non‑adherence from true corticosteroid resistance using objective tests such as remote monitoring of ICS use and exhaled nitric oxide suppression testing (rasp.org.uk).
At the recent RASP‑UK Annual Consortium Meeting, researchers reported published findings from one strand of the programme that evaluated outcomes when people with severe asthma do not adhere to their prescribed treatment plans. These results underscore that non‑adherence is both common and clinically important; it can be mistaken for refractory disease, leading to unnecessary treatment escalation including inappropriate biologic prescribing. Objective adherence assessment, such as medication possession ratios and biomarker‑guided adherence tests, helps refine patient characterization, ensuring that biologic therapies are reserved for those who are adherent yet remain uncontrolled despite optimal standard care (rasp.org.uk).
Importantly, actively involving patients in research enhances the relevance, feasibility, and impact of clinical studies. Drawing on evidence from systematic reviews, when patients are engaged early and meaningfully in research design and execution, studies are more likely to address questions that matter to patients, improve enrolment and retention, and enhance translation of findings into practice [9][10][11]. In RASP‑UK, the Patient Input Platform comprising people living with severe asthma has informed study design, recruitment strategies, and dissemination planning; this has helped ensure that research outcomes align with patient needs, increased engagement, and improved uptake of findings in clinical practice.
So, what are the five key principles for successful and meaningful patient involvement identified in the source material from RASP‑UK?
In essence, integrating objective pre‑biologic assessments with authentic patient partnership ensures that advanced therapies are used where they will truly make a difference, making precision asthma care both effective and patient‑centred.
References: